Standard BioTools Inc. (Nasdaq: LAB)

https://www.standardbio.com

Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. *

	Start	2022-04-04 renamed
	Group	Standard BioTools (Group)
	Predecessor	Fluidigm Corporation (Nasdaq: FLDM)
	Industry	microfluidics technology
	Industry 2	laboratory equipment and instruments

	Region	South San Francisco, CA
	Country	United States (USA)
	Street	2 Tower Place Suite 2000
	City	94080 South San Francisco, CA
		Address record changed: 2024-08-12

Basic data	Employees	E: 501 to 1,000 (2023-12-31)
	Currency	USD
	Annual sales	106,340,000 (revenue, total, consolidated (2023) 2023-12-31)
	Profit	-74,656,000 (2023-12-31)
	Cash	114,895,000 (2023-12-31)

		* Document for »About Section«: Standard BioTools Inc.. (8/6/24). "Press Release: Standard BioTools to Participate in Upcoming Investor Conferences". South San Francisco, CA.

		Record changed: 2024-08-13